New England Biolabs Unveils Advanced Technology at 2026 AGBT Meeting New England Biolabs will showcase its latest advancements in Next Generation Sequencing at the 2026 AGBT Meeting, including novel solutions for RNA and long-read sequencing.

New England Biolabs Unveils Advanced Technology at 2026 AGBT Meeting #USA #Orlando #New_England_Biolabs #NGS_Technology #NEBNext

DNAe Launches Early Access Program for New NGS Diagnostic Platform LiDia-SEQ™ DNAe has initiated an Early Access Program for its innovative LiDia-SEQ™ diagnostic system, enabling hospitals to trial its groundbreaking tests. This offers transformative potential for diagnostics.

DNAe Launches Early Access Program for New NGS Diagnostic Platform LiDia-SEQ™ #United_States #Carlsbad #NGS_Technology #DNAe #LiDia-SEQ

Genomics Market Set to Reach $85.09 Billion by 2030 with Rapid Growth The Genomics Market is expected to rise to $85.09 billion by 2030, growing at a CAGR of 12.6%. This growth is driven by various advancements and increased funding.

Genomics Market Set to Reach $85.09 Billion by 2030 with Rapid Growth #USA #Delray_Beach #Precision_Medicine #Genomics_Market #NGS_Technology

Pillar Biosciences Launches Innovative NGS Panel for Tumor Profiling Pillar Biosciences has unveiled its latest oncoReveal Lymphoid NGS panel, enhancing the efficiency of tumor profiling in lymphoid malignancies.

Pillar Biosciences Launches Innovative NGS Panel for Tumor Profiling #USA #Natick #Pillar_Biosciences #oncoReveal #NGS_Technology

Liquid Biopsy Market Forecast to Reach $7.05 Billion by 2030 Driven by Increasing Cancer Incidences The liquid biopsy market is projected to grow to $7.05 billion by 2030. This growth is driven by rising cancer cases and advancements in diagnostic technologies.

Liquid Biopsy Market Forecast to Reach $7.05 Billion by 2030 Driven by Increasing Cancer Incidences #None #Liquid_Biopsy #cancer_detection #NGS_Technology

Pillar Biosciences Secures $34.5M Funding to Expand Clinical Testing and Partnerships Pillar Biosciences announces $34.5 million in funding to enhance its clinical testing capabilities, support partnerships, and bolster growth.

Pillar Biosciences Secures $34.5M Funding to Expand Clinical Testing and Partnerships #United_States #oncology #Natick #Pillar_Biosciences #NGS_Technology

Gene Solutions and Element Biosciences Partner to Transform Next-Generation Sequencing Globally Gene Solutions and Element Biosciences unite to enhance next-generation sequencing technology, aiming to democratize access and revolutionize genetic testing.

Gene Solutions and Element Biosciences Partner to Transform Next-Generation Sequencing Globally #Vietnam #Ho_Chi_Minh_City #Element_Biosciences #Gene_Solutions #NGS_Technology